Cargando…

Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial

Background and aims: We aimed to evaluate the efficacy and tolerability of grazoprevir/elbasvir in patients with chronic genotype 1 hepatitis C virus (HCV) and HIV co-infection who experienced peginterferon alfa plus ribavirin (PegIFN/RBV) (clinicaltrials.gov NCT03098121). Methods: This non-randomiz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Yi-Chun, Li, Shih-Wei, Ku, Shin-Yen, Hsieh, Hui-Ting, Lin, Mei-Hui, Chang, Shu-Yin, Wu, Wei-Wei, Sun, Na-Lee, Cheng, Shu-Hsing, Cheng, Chien-Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489556/ https://www.ncbi.nlm.nih.gov/pubmed/31114268 http://dx.doi.org/10.2147/IDR.S206938

Ejemplares similares

The efficacy and safety of elbasvir/grazoprevir treatment in HCV genotype 1 patients in Taiwan
por: Tsai, Tzu‐Cheng, et al.
Publicado: (2019)

Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient
por: Chen, Jin, et al.
Publicado: (2020)

Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial
por: Zhdanov, Konstantin, et al.
Publicado: (2020)

Cost-Efficacy Analysis of Peginterferon alfa-2b plus Ribavirin Compared With Peginterferon alfa-2a plus Ribavirin for the Treatment of Chronic Hepatitis C
por: Malone, Daniel C., et al.
Publicado: (2005)

Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients
por: Ji, Qinghua, et al.
Publicado: (2021)

Pharmacokinetic similarity demonstrated after crushing of the elbasvir/grazoprevir fixed-dose combination tablet for HCV infection
por: Pijnenburg, Daniëlle W M, et al.
Publicado: (2020)

A meta-analysis that compares the use of either peginterferon-α2a or peginterferon-α2b plus ribavirin for HCV infection
por: Xiao, Nan, et al.
Publicado: (2010)

The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study
por: Kumada, Hiromitsu, et al.
Publicado: (2016)

Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
por: Liu, Chen-Hua, et al.
Publicado: (2020)

A Retrospective Cohort Study: Safety and Effectiveness of Elbasvir/Grazoprevir ± Ribavirin Compared With Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir ± Ribavirin in Patients With Chronic Hepatitis C Genotype 1 Infection
por: Hung, Hsuan-Yu, et al.
Publicado: (2021)

Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C
por: Bell, Allison M., et al.
Publicado: (2016)

Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence
por: Morikawa, Kenichi, et al.
Publicado: (2018)

Prediction of Treatment Week Eight Response & Sustained Virologic Response in Patients Treated with Boceprevir Plus Peginterferon Alfa and Ribavirin
por: Thompson, Alex, et al.
Publicado: (2014)

Spotlight on grazoprevir–elbasvir once-daily combination and its potential in the treatment of hepatitis C
por: Suraweera, Duminda, et al.
Publicado: (2016)

Elbasvir/Grazoprevir, an Alternative in Antiviral Hepatitis C Therapy in Patients under Amiodarone Treatment
por: Weiss, Lina, et al.
Publicado: (2018)

Patient-reported outcomes in individuals with hepatitis C virus infection treated with elbasvir/grazoprevir
por: Ng, Xinyi, et al.
Publicado: (2018)

No Pharmacokinetic Interaction Between the Hepatitis C Virus Inhibitors Elbasvir/Grazoprevir and Famotidine or Pantoprazole
por: Feng, H‐P, et al.
Publicado: (2017)

Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review
por: Liu, Jinyu, et al.
Publicado: (2022)

Elbasvir/grazoprevir in children aged 3–18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study
por: Gonzalez-Peralta, Regino P., et al.
Publicado: (2023)

Chronic HCV treatment with peginterferon-ribavirin and severe tuberculosis re-activation
por: Manfredi, Roberto, et al.
Publicado: (2010)

A Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/Elbasvir in Healthy Chinese Participants
por: Li, Haiyan, et al.
Publicado: (2020)

Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study
por: Liu, Chen-Hua, et al.
Publicado: (2015)

Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus
por: Kim, Yu Jin, et al.
Publicado: (2011)

High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice
por: Heo, Nae-Yun, et al.
Publicado: (2013)

Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study
por: Hayashi, Norio, et al.
Publicado: (2014)

No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Methadone in Participants Receiving Maintenance Opioid Agonist Therapy
por: Feng, Hwa‐Ping, et al.
Publicado: (2018)

Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C–Viremic Donor to Uninfected Recipient Kidney Transplantation
por: Sise, Meghan E., et al.
Publicado: (2020)

Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial
por: Liu, Chen-Hua, et al.
Publicado: (2015)

Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study
por: Silva, Giovanni Faria, et al.
Publicado: (2013)

Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy
por: Hézode, Christophe, et al.
Publicado: (2019)

An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection
por: Lee, Youn Jae, et al.
Publicado: (2019)

Effectiveness of Elbasvir/Grazoprevir in US Veterans with Chronic Hepatitis C Virus Genotype 1b Infection
por: Puenpatom, Amy, et al.
Publicado: (2020)

Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C
por: Lu, Ming-Ying, et al.
Publicado: (2016)

Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients
por: Yang, Chi-Chieh, et al.
Publicado: (2015)

Efficacy and safety of elbasvir/grazoprevir in treatment‐naive Chinese adults with hepatitis C virus infection: A randomized trial
por: Wei, Lai, et al.
Publicado: (2020)

Elbasvir/grazoprevir in Asia‐Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection
por: George, Jacob, et al.
Publicado: (2018)

Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis
por: Yao, Yinan, et al.
Publicado: (2017)

Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy
por: Sulejmani, Nimisha, et al.
Publicado: (2018)

Treatment With Grazoprevir/Elbasvir for Renal Transplant Recipients With Chronic Hepatitis C Virus Infection and Impaired Allograft Function
por: Eisenberger, Ute, et al.
Publicado: (2018)

Peginterferon Alfa-2a plus Ribavirin in Japanese Patients Infected with Hepatitis C Virus Genotype 2 Who Failed Previous Interferon Therapy
por: Kanda, Tatsuo, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_gg03qv92m4gq8kld1o4k56ermb